COX-2 is an enzyme that is thought to assist in upregulating bcl-2, a protein that prevents apoptosis, or programmed cell death, in cells. Bcl-2 is thought to be the cause behind many cancers. COX-2 is expressed in abnormally high concentrations in cancers of the breast, cervix, stomach and pancreas, possibly upregulating the bcl-2 protein in these tissues. Thus, the aim of the experiment was to see how inhibiting COX-2 would affect the viability of cancer cells. Two breast cancer cell lines, HTB-129 and HTB-132 and one normal breast cell line, 184-A1, were exposed to concentrations of 0.18 µmol, 0.36 µmol and 0.54 µmol of a selective COX-2 inhibitor called meloxicam for 24 and 48 hours. The 184-A1 cell line showed no response to the COX-2 inhibitor, showing that meloxicam is safe to use on normal body cells. However, the viability of the HTB-129 and HTB-132 cell lines went down with increasing concentrations of meloxicam. This was found using an MTT assay. An apoptosis assay confirmed that the cancerous cells were dying due to apoptosis. A western blot for bcl-2 showed that COX-2 inhibition caused by increasing concentrations of meloxicam caused a reduction in bcl-2 expression in a dose-dependent manner.